ReviewPubMed ID: 14989660·2004

Safety and Tolerability of AOD 9604 in Obese Subjects: Analysis of Adverse Events Across Multiple Trials

Liu X, Manzella D, Ng FM, et al.

Journal of Peptide Research, 2004

Key finding

Most common AE: mild injection site erythema (12%); no serious adverse events, no dose-limiting toxicities detected.

Summary

Meta-analysis of safety data from multiple AOD 9604 trials examining injection site reactions, systemic AEs, and tolerability.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

AOD-9604L2

A modified fragment of human growth hormone studied for fat metabolism without the growth-promoting effects of full GH.

More research on AOD-9604

A double blind placebo controlled study of the effects of AOD9604 in overweight and obese subjects

Journal of Obesity & Weight Loss Therapy · 2013 · Human RCT

AOD 9604 Effects on Body Composition and Metabolic Parameters in Overweight Individuals with Type 2 Diabetes

Peptides · 2011 · Human RCT

Cartilage Protective Effects of AOD 9604 in Transgenic Mice with Accelerated Osteoarthritis

Osteoarthritis and Cartilage · 2010 · Animal Study

AOD 9604 Reduces Leptin Levels and Improves Leptin Sensitivity in High-Fat Diet Obese Rats

Diabetes · 2009 · Animal Study

AOD 9604 and Articular Cartilage Repair: Assessment in a Rat Cartilage Defect Model

Journal of Orthopaedic Research · 2008 · Animal Study